Vondran Florian W R, Oldhafer Felix, Ringe Kristina I, Wirth Thomas C, Kleine Moritz, Jäger Mark D, Klempnauer Juergen, Bektas Hueseyin
Regenerative Medicine and Experimental Surgery (ReMediES), Department of General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany.
Department of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.
ANZ J Surg. 2018 Apr;88(4):E324-E328. doi: 10.1111/ans.13944. Epub 2017 Apr 16.
Recently a procedure termed 'Associating Liver Partition and Portal vein ligation for Staged hepatectomy' (ALPPS) was developed to increase the resectability of marginally resectable or locally unresectable liver tumours. This study focused on the application of ALPPS in patients with advanced colorectal liver metastases (CRLM) and pre-operative chemotherapy, with the aim to investigate whether the latter still allows for sufficient hypertrophy of the future liver remnant (FLR) following the first step of ALPPS.
Retrospective analysis was performed on six patients suffering from advanced CRLM. Analyses comprised demographical and basic clinical data, the perioperative courses as well as short- and long-term outcomes.
All patients presented with bilobular CRLM and pre-operative chemotherapy of at least 6 months. Extended right hemihepatectomy was performed in all cases, four patients additionally received atypical resections in segments II/III. Mean FLR prior to step 1 of ALPPS was 397.9 cm (121-753 cm ), on average representing 20.9% of the total liver volume (13.2-27.1%). A mean hypertrophy of the FLR of 67.9% (32.5-94.1%) was achieved. Overall, severe morbidity (Dindo Clavien >3a) occurred in two patients. Following completion of ALPPS, mean post-operative disease-free survival was 5.7 months (2.6-8.9 months).
Despite pre-operative chemotherapy, ALPPS seems to result in adequate liver hypertrophy, preventing post-operative small-for-size syndrome. However, there might be a high risk of tumour recurrence in patients with an aggressive tumour biology.
最近开发了一种名为“联合肝脏分隔和门静脉结扎分期肝切除术”(ALPPS)的手术方法,以提高边缘可切除或局部不可切除肝肿瘤的可切除性。本研究聚焦于ALPPS在晚期结直肠癌肝转移(CRLM)患者及术前化疗中的应用,旨在调查在ALPPS第一步之后,术前化疗是否仍能使未来肝残余(FLR)实现充分肥大。
对6例晚期CRLM患者进行回顾性分析。分析内容包括人口统计学和基础临床数据、围手术期过程以及短期和长期结果。
所有患者均表现为双叶CRLM且接受了至少6个月的术前化疗。所有病例均进行了扩大右半肝切除术,4例患者在Ⅱ/Ⅲ段还接受了非典型切除术。ALPPS第一步之前的平均FLR为397.9 cm³(121 - 753 cm³),平均占肝脏总体积的20.9%(13.2% - 27.1%)。FLR平均肥大67.9%(32.5% - 94.1%)。总体而言,2例患者发生了严重并发症(Dindo Clavien>3a)。完成ALPPS后,平均术后无病生存期为5.7个月(2.6 - 8.9个月)。
尽管进行了术前化疗,但ALPPS似乎能导致足够的肝脏肥大,预防术后小肝综合征。然而,对于具有侵袭性肿瘤生物学行为的患者,可能存在较高的肿瘤复发风险。